Cargando…
Uveitis and Other Ocular Complications Following COVID-19 Vaccination
Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704915/ https://www.ncbi.nlm.nih.gov/pubmed/34945256 http://dx.doi.org/10.3390/jcm10245960 |
_version_ | 1784621820761079808 |
---|---|
author | Bolletta, Elena Iannetta, Danilo Mastrofilippo, Valentina De Simone, Luca Gozzi, Fabrizio Croci, Stefania Bonacini, Martina Belloni, Lucia Zerbini, Alessandro Adani, Chantal Fontana, Luigi Salvarani, Carlo Cimino, Luca |
author_facet | Bolletta, Elena Iannetta, Danilo Mastrofilippo, Valentina De Simone, Luca Gozzi, Fabrizio Croci, Stefania Bonacini, Martina Belloni, Lucia Zerbini, Alessandro Adani, Chantal Fontana, Luigi Salvarani, Carlo Cimino, Luca |
author_sort | Bolletta, Elena |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age of 49.8 years (range 18–83 years). The cases reported were three herpetic keratitis, two anterior scleritis, five anterior uveitis (AU), three toxoplasma retinochoroiditis, two Vogt-Koyanagi-Harada (VKH) disease reactivations, two pars planitis, two retinal vasculitis, one bilateral panuveitis in new-onset Behçet’s disease, three multiple evanescent white dot syndromes (MEWDS), one acute macular neuroretinopathy (AMN), five retinal vein occlusions (RVO), one non-arteritic ischemic optic neuropathy (NAION), three activations of quiescent choroidal neovascularization (CNV) secondary to myopia or uveitis, and one central serous chorioretinopathy (CSCR). Mean time between vaccination and ocular complication onset was 9.4 days (range 1–30 days). Twenty-three cases occurred after Pfizer-BioNTech vaccination (BNT162b2 mRNA), 7 after Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19), 3 after ModernaTX vaccination (mRNA-1273), and 1 after Janssen Johnson & Johnson vaccine (Ad26.COV2). Uveitis and other ocular complications may develop after the administration of COVID-19 vaccine. |
format | Online Article Text |
id | pubmed-8704915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87049152021-12-25 Uveitis and Other Ocular Complications Following COVID-19 Vaccination Bolletta, Elena Iannetta, Danilo Mastrofilippo, Valentina De Simone, Luca Gozzi, Fabrizio Croci, Stefania Bonacini, Martina Belloni, Lucia Zerbini, Alessandro Adani, Chantal Fontana, Luigi Salvarani, Carlo Cimino, Luca J Clin Med Article Coronavirus disease 2019 (COVID-19) vaccines can cause transient local and systemic post-vaccination reactions. The aim of this study was to report uveitis and other ocular complications following COVID-19 vaccination. The study included 42 eyes of 34 patients (20 females, 14 males), with a mean age of 49.8 years (range 18–83 years). The cases reported were three herpetic keratitis, two anterior scleritis, five anterior uveitis (AU), three toxoplasma retinochoroiditis, two Vogt-Koyanagi-Harada (VKH) disease reactivations, two pars planitis, two retinal vasculitis, one bilateral panuveitis in new-onset Behçet’s disease, three multiple evanescent white dot syndromes (MEWDS), one acute macular neuroretinopathy (AMN), five retinal vein occlusions (RVO), one non-arteritic ischemic optic neuropathy (NAION), three activations of quiescent choroidal neovascularization (CNV) secondary to myopia or uveitis, and one central serous chorioretinopathy (CSCR). Mean time between vaccination and ocular complication onset was 9.4 days (range 1–30 days). Twenty-three cases occurred after Pfizer-BioNTech vaccination (BNT162b2 mRNA), 7 after Oxford-AstraZeneca vaccine (ChAdOx1 nCoV-19), 3 after ModernaTX vaccination (mRNA-1273), and 1 after Janssen Johnson & Johnson vaccine (Ad26.COV2). Uveitis and other ocular complications may develop after the administration of COVID-19 vaccine. MDPI 2021-12-19 /pmc/articles/PMC8704915/ /pubmed/34945256 http://dx.doi.org/10.3390/jcm10245960 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bolletta, Elena Iannetta, Danilo Mastrofilippo, Valentina De Simone, Luca Gozzi, Fabrizio Croci, Stefania Bonacini, Martina Belloni, Lucia Zerbini, Alessandro Adani, Chantal Fontana, Luigi Salvarani, Carlo Cimino, Luca Uveitis and Other Ocular Complications Following COVID-19 Vaccination |
title | Uveitis and Other Ocular Complications Following COVID-19 Vaccination |
title_full | Uveitis and Other Ocular Complications Following COVID-19 Vaccination |
title_fullStr | Uveitis and Other Ocular Complications Following COVID-19 Vaccination |
title_full_unstemmed | Uveitis and Other Ocular Complications Following COVID-19 Vaccination |
title_short | Uveitis and Other Ocular Complications Following COVID-19 Vaccination |
title_sort | uveitis and other ocular complications following covid-19 vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704915/ https://www.ncbi.nlm.nih.gov/pubmed/34945256 http://dx.doi.org/10.3390/jcm10245960 |
work_keys_str_mv | AT bollettaelena uveitisandotherocularcomplicationsfollowingcovid19vaccination AT iannettadanilo uveitisandotherocularcomplicationsfollowingcovid19vaccination AT mastrofilippovalentina uveitisandotherocularcomplicationsfollowingcovid19vaccination AT desimoneluca uveitisandotherocularcomplicationsfollowingcovid19vaccination AT gozzifabrizio uveitisandotherocularcomplicationsfollowingcovid19vaccination AT crocistefania uveitisandotherocularcomplicationsfollowingcovid19vaccination AT bonacinimartina uveitisandotherocularcomplicationsfollowingcovid19vaccination AT bellonilucia uveitisandotherocularcomplicationsfollowingcovid19vaccination AT zerbinialessandro uveitisandotherocularcomplicationsfollowingcovid19vaccination AT adanichantal uveitisandotherocularcomplicationsfollowingcovid19vaccination AT fontanaluigi uveitisandotherocularcomplicationsfollowingcovid19vaccination AT salvaranicarlo uveitisandotherocularcomplicationsfollowingcovid19vaccination AT ciminoluca uveitisandotherocularcomplicationsfollowingcovid19vaccination |